BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27819678)

  • 21. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
    Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
    Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KDM1A triggers androgen-induced miRNA transcription via H3K4me2 demethylation and DNA oxidation.
    Yang S; Zhang J; Zhang Y; Wan X; Zhang C; Huang X; Huang W; Pu H; Pei C; Wu H; Huang Y; Huang S; Li Y
    Prostate; 2015 Jun; 75(9):936-46. PubMed ID: 25728837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
    Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
    Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
    Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
    PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a.
    Zhao XY; Boyle B; Krishnan AV; Navone NM; Peehl DM; Feldman D
    J Urol; 1999 Dec; 162(6):2192-9. PubMed ID: 10569618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
    Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells.
    Lu Y; Feng F; Yang Y; Gao X; Cui J; Zhang C; Zhang F; Xu Z; Qv J; Wang C; Zeng Z; Zhu Y; Yang Y
    Cell Signal; 2013 Feb; 25(2):479-89. PubMed ID: 23153584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines.
    Bennett NC; Hooper JD; Johnson DW; Gobe GC
    Prostate; 2014 May; 74(5):478-87. PubMed ID: 24375805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression.
    Yıldırım-Buharalıoğlu G
    Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
    Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
    Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer.
    Ha S; Iqbal NJ; Mita P; Ruoff R; Gerald WL; Lepor H; Taneja SS; Lee P; Melamed J; Garabedian MJ; Logan SK
    Oncogene; 2013 Aug; 32(34):3992-4000. PubMed ID: 22986532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.
    Karacosta LG; Foster BA; Azabdaftari G; Feliciano DM; Edelman AM
    J Biol Chem; 2012 Jul; 287(29):24832-43. PubMed ID: 22654108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway.
    Lee SO; Lou W; Hou M; Onate SA; Gao AC
    Oncogene; 2003 Sep; 22(39):7981-8. PubMed ID: 12970746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
    Ben Jemaa A; Sallami S; Céraline J; Oueslati R
    Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prostate cancer-up-regulated Myc-associated zinc-finger protein (MAZ) modulates proliferation and metastasis through reciprocal regulation of androgen receptor.
    Jiao L; Li Y; Shen D; Xu C; Wang L; Huang G; Chen L; Yang Y; Yang C; Yu Y; Sun Y
    Med Oncol; 2013; 30(2):570. PubMed ID: 23609189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer.
    Clark EL; Coulson A; Dalgliesh C; Rajan P; Nicol SM; Fleming S; Heer R; Gaughan L; Leung HY; Elliott DJ; Fuller-Pace FV; Robson CN
    Cancer Res; 2008 Oct; 68(19):7938-46. PubMed ID: 18829551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin.
    Luo Y; Vlaeminck-Guillem V; Baron S; Dallel S; Zhang CX; Le Romancer M
    J Exp Clin Cancer Res; 2021 Aug; 40(1):270. PubMed ID: 34446068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
    Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
    Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.